Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BP22042013 is an investigational dietary intervention identifier used in the clinical trial NCT02614599, titled 'Neurocognitive and Neurobiological Improvement in ADHD Children by Modification of Dietary Protein (BrainProtein).' Sponsored by the Spanish Foundation for Neurometrics Development, it refers to a high-protein dietary supplement regimen evaluated for its potential to improve neurocognitive and neurobiological outcomes in children aged 7–12 diagnosed with Attention Deficit Hyperactivity Disorder (ADHD) or Attention Deficit Disorder (ADD). The intervention is compared against a low-carbohydrate diet over a three-month period, with researchers measuring changes in brain connectivity via EEG and event-related potentials (ERP), as well as behavioral improvements. The regimen aims to leverage nutritional therapy to modulate brain function and behavior in pediatric populations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on BP22042013 (Spanish Foundation for Neurometrics).